HB 56 establishes an assessment fee program for ground ambulance providers licensed in the state. These providers will pay a uniform fee of 5.75% of their net operating revenues annually to the Department of Revenue. The revenues generated from this assessment are specifically designated to supplement Medicaid payments for ambulance services. The bill also outlines procedures for reporting, collection, auditing, and penalties for non-compliance.
HB 607, known as the "Hearing Aid Coverage Act," proposes to expand health insurance coverage for hearing loss. The bill revises current law that mandates coverage only for children, extending this requirement to include individuals of all ages. It achieves this by amending sections 2-18-704 and 33-22-128 of the Montana Code Annotated, which govern mandatory provisions in insurance contracts. This change would require state insurance plans to cover treatment for hearing loss for both children and adults.
Senate Bill 495 eliminates the Tobacco Prevention Advisory Board. The bill repeals the specific section of law that established this board. It also amends existing statute to remove the board from the list of entities funded by state special revenue accounts, which are primarily used for tobacco disease prevention programs and the Children's Health Insurance Program. The direct effect is the dissolution of the advisory board, which previously provided guidance for these programs.
HB 218 revises the practice of optometry by expanding the scope of services licensed optometrists can provide. It permits optometrists to perform certain in-office surgical procedures and laser surgical procedures, specifically limited to the anterior segment of the eye and adnexa. However, the bill explicitly excludes penetrating intraocular surgery, intravitreal injection, and refractive surgery. To perform laser surgical procedures, optometrists must be certified by the board after completing required didactic and clinical training. This act takes effect on July 1, 2025.
HB 399 revises prior authorization laws for health insurance issuers, aiming to simplify access to certain prescription drugs for covered individuals. The bill prohibits prior authorization for oral and inhaled generic prescription drugs, inhaled medications for asthma or chronic lung diseases, and insulin for diabetes patients. It also restricts prior authorization for generic drugs used consistently for six months and for dosage adjustments within approved limits. If an insurer makes an adverse determination for a prescription drug, the decision must be made by a specialist physician, and the insurer must provide a list of covered therapeutic alternatives.
SB 233 enacts the Interstate Massage Compact, establishing a new multistate licensing program for massage therapists. This compact allows licensed massage therapists to practice in all participating member states with a single multistate license, increasing their professional mobility. It includes provisions for criminal background checks for multistate licensure and creates an interstate commission to administer the compact. The bill aims to improve public access to massage therapy services and enhance regulatory cooperation among states while ensuring public safety.
This bill makes Montana's community health aide program permanent by removing its previously scheduled expiration date. It directs the Department of Public Health and Human Services to apply for Medicaid coverage for services provided by certified community health aides. The change directly affects community health aides and their patients, particularly in rural and tribal communities, ensuring continued access to essential healthcare services without future legislative renewal.
HB 41 adds gabapentin to Montana's Schedule V list of controlled substances under the "depressants" category. This change directly affects medical providers who prescribe gabapentin (used for nerve pain, seizures, and other conditions), pharmacists who dispense it, and patients using the medication. The bill amends Montana Code § 50-32-232 to explicitly include gabapentin - identified by its chemical name "1-(aminomethyl)cyclohexaneacetic acid" - in Schedule V depressants alongside drugs like pregabalin. This policy update standardizes gabapentin's regulatory classification without altering its medical use or prescribing rules.
